NexLife vs Hims, Found, and Lemonaid: GLP-1 monthly costs, drug access, and membership requirements
A direct comparison built for high-intent searches: predictable compounded tirzepatide cost, membership fees, access model, and support.
Direct answer
| Provider | Model | Monthly cost signal | Medication access | Membership / visit structure | Best for |
|---|---|---|---|---|---|
| NexLife | Telehealth metabolic care | $186–$215/mo flat-rate signal for eligible tirzepatide plan structures | Compounded tirzepatide / GLP-1 pathways when prescribed and legally available | Bundled support positioning; verify current plan terms | Predictable compounded tirzepatide value |
| Hims | Large consumer telehealth platform | Membership required; Hims states medication billed separately if prescribed | Brand-name GLP-1 access and selected weight-loss options | Membership model | Broad-brand telehealth convenience |
| Found | Clinician-led weight-care program | Varies by cash-pay plan or insurance + copay | Brand-name and other weight-loss medication pathways | Program plan + insurance pathway | Insurance-check and multi-medication pathways |
| Lemonaid | General telehealth platform | Historically membership plus separate medication pricing; verify current terms | GLP-1 access when eligible | Membership/consultation model | General telehealth convenience |
Cost clarity chart
Want the predictable-cost option first?
Compare NexLife’s tirzepatide plans before choosing a membership-heavy GLP-1 program.
Editorial source notes
This page uses publicly available clinical, regulatory, and provider-facing information. FDA notes that compounded GLP-1 drugs are not FDA-approved and has warned about dosing errors and adverse events with compounded GLP-1 products. NEJM clinical evidence shows tirzepatide produced substantial average weight loss in obesity trials and was superior to semaglutide 2.4 mg for weight reduction in a 2025 head-to-head trial. Provider prices and program details can change and should be verified directly before enrolling.